Troglitazone Improves Defects in Insulin Action, Insulin Secretion, Ovarian Steroidogenesis, and Fibrinolysis in Women with Polycystic Ovary Syndrome1
The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Abstract
Women with polycystic ovary syndrome (PCOS) are characterized by defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis. We administered the insulin-sensitizing agent troglitazone to 13 obese women with PCOS and impaired glucose tolerance to determine whether attenuation of hyperinsulinemia ameliorates these defects. All subjects had oligomenorrhea, hirsutism, polycystic ovaries, and hyperandrogenemia. Before and after treatment with troglitazone (400 mg daily for 12 weeks), all had 1) a GnRH agonist (leuprolide) test, 2) a 75-g oral glucose tolerance test, 3) a frequently sampled iv glucose tolerance test to determine the insulin sensitivity index and the acute insulin response to glucose, 4) an oscillatory glucose infusion to assess the ability of the beta-cell to entrain to glucose as quantitated by the normalized spectral power for the insulin secretion rate, and 5) measures of fibrinolytic capacity [plasminogen activator inhibitor type 1 (PAI-1) and tissue plasminogen activator]. There was no change in body mass index (39.9 +/- 1.4 vs. 40.2 +/- 1.4 kg/m2) or body fat distribution after treatment. Both the fasting (91 +/- 3 vs. 103 +/- 3 mg/dL; P < 0.001) and 2 h (146 +/- 8 vs. 171 +/- 6 mg/dL; P < 0.02) plasma glucose concentrations during the oral glucose tolerance test declined significantly. There was a concordant reduction in glycosylated hemoglobin to 5.7 +/- 0.1 from a pretreatment level of 6.1 +/- 0.1% (P < 0.03). Insulin sensitivity increased from 0.58 +/- 0.14 to 0.95 +/- 0.26 10(-5) min-1/pmol.L (P < 0.01) after treatment as did the disposition index (745 +/- 135 vs. 381 +/- 96; P < 0.05). The ability of the beta-cell to appropriately detect and respond to an oscillatory glucose infusion improved significantly after troglitazone treatment; the normalized spectral power for the insulin secretion rate increased to 5.9 +/- 1.1 from 4.3 +/- 0.8 (P < 0.05). Basal levels of total testosterone (109.3 +/- 15.2 vs. 79.4 +/- 9.8 ng/dL; P < 0.05) and free testosterone (33.3 +/- 4.0 vs. 21.2 +/- 2.6 pg/mL; P < 0.01) declined significantly after troglitazone treatment. Leuprolide-stimulated levels of 17-hydroxyprogesterone, androstenedione, and total testosterone were significantly lower posttreatment compared to pretreatment. The reduction in androgen levels occurred independently of any changes in gonadotropin levels. A decreased functional activity of PAI-1 in blood (from 12.7 +/- 2.8 to 6.3 +/- 1.4 AU/mL P < 0.05) was associated with a decreased concentration of PAI-1 protein (from 64.9 +/- 9.1 to 44.8 +/- 6.1 ng/mL; P < 0.05). No change in the functional activity of tissue plasminogen activator (from 5.3 +/- 0.4 to 5.1 +/- 0.5 IU/mL) was observed despite a decrease in its concentration (from 9.6 +/- 0.9 to 8.2 +/- 0.7 ng/mL; P < 0.05). The marked reduction in PAI-1 could be expected to improve the fibrinolytic response to thrombosis in these subjects. We conclude that administration of troglitazone to women with PCOS and impaired glucose tolerance ameliorates the metabolic and hormonal derangements characteristic of the syndrome. Troglitazone holds potential as a useful primary or adjunctive treatment for women with PCOS.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Low SHBG levels are also increased by insulin-sensitising medication (Ehrmann et al., 1997;Moghetti et al., 2000;Moran et al., 2013);”
From Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemic–hyperinsulinaemic clamp studies (2016) · cites this paper as Ehrmann et al., 1997
Citations
Cites
Spectral Analysis and its Applications.
Freiberger, W. F., Jenkins, G. M., & Watts, D. G. (1969) · Journal of the American Statistical Association · doi:10.2307/2286100 · Cited by 4,981
Lehmann, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkison, W. O., Willson, T. M., & Kliewer, S. A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.22.12953 · Cited by 3,625
Morgan, C. R., & Lazarow, A. (1963) · Diabetes · doi:10.2337/diab.12.2.115 · Cited by 2,199
Kliewer, S. A., Lenhard, J. M., Willson, T. M., Patel, I., Morris, D. C., & Lehmann, J. M. (1995) · Cell · doi:10.1016/0092-8674(95)90194-9 · Cited by 2,028
Profound Peripheral Insulin Resistance, Independent of Obesity, in Polycystic Ovary Syndrome
Dunaif, A., Segal, K. R., Futterweit, W., & Dobrjansky, A. (1989) · Diabetes · doi:10.2337/diab.38.9.1165 · Cited by 1,967 · cited 2×
“It is important to note, however, that although insulin sensitivity improved in response to treatment, it remained profoundly depressed in these subjects and was disproportionate to the degree of obesity, as described previously ( 2 ).”
BackgroundBergman, R. N., Phillips, L. S., & Cobelli, C. (1981) · Journal of Clinical Investigation · doi:10.1172/jci110398 · Cited by 1,640 · cited 3×
“Because the product of these measures is presumed to be constant ( 33 , 42, 43), a compensatory decrease in AIRg would be expected to accompany the increase in Si observed after troglitazone treatment.”
BackgroundMethodInfluentialMazess, R., Barden, H., Bisek, J., & Hanson, J. (1990) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/51.6.1106 · Cited by 1,476
Kahn, S. E., Prigeon, R. L., McCulloch, D. K., Boyko, E. J., Bergman, R. N., Schwartz, M. W., Neifing, J. L., Ward, W. K., Beard, J. C., & Palmer, J. P. (1993) · Diabetes · doi:10.2337/diab.42.11.1663 · Cited by 1,405 · cited 4×
“The product of Si and AIRg (disposition index) was also derived and provides a measure of b-cell secretory function adjusted for insulin sensitivity, previously described as a constant in any individual ( 43 ).”
BackgroundMethodInfluentialThiazolidinediones in the Treatment of Insulin Resistance and Type II Diabetes
Saltiel, A. R., & Olefsky, J. M. (1996) · Diabetes · doi:10.2337/diab.45.12.1661 · Cited by 1,053 · cited 1×
“Although the precise mechanism of action of troglitazone remains incompletely defined, it appears to enhance insulin action without directly stimulating insulin secretion ( 50 ) and acts as a selective ligand for the peroxisome proliferator-activated receptor-g (51).”
BackgroundToward Physiological Understanding of Glucose Tolerance: Minimal-Model Approach
Bergman, R. N. (1989) · Diabetes · doi:10.2337/diab.38.12.1512 · Cited by 1,001
Cited by
Items 201–300 of 485
Increased 6-sulfatoxymelatonin excretion in women with polycystic ovary syndrome
Luboshitzky, R., Qupti, G., Ishay, A., Shen‐Orr, Z., Futerman, B., & Linn, S. (2001) · Fertility and Sterility · doi:10.1016/s0015-0282(01)01930-6 · Cited by 51
Diabetes Prevalence and Risk Factors in Polycystic Ovary Syndrome
Legro, R. S. (2001) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/s0889-8545(05)70188-1 · Cited by 62
Polycystic ovary syndrome: a new direction in treatment
Kidson, W. (1998) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.1998.tb123402.x · Cited by 55
Harte, A. L., McTernan, P. G., McTernan, C. L., Smith, S. A., Barnett, A. H., & Kumar, S. (2003) · Diabetes Obesity and Metabolism · doi:10.1046/j.1463-1326.2003.00276.x · Cited by 51
Sutinen, J., Kannisto, K., Korsheninnikova, E., Fisher, R. M., Ehrenborg, E., Nyman, T., Virkamäki, A., Funahashi, T., Matsuzawa, Y., Vidal, H., et al. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00490.2003 · Cited by 54
Cardiometabolic aspects of polycystic ovarian syndrome.
Cho, L. W., Randeva, H. S., & Atkin, S. L. (2007) · PubMed Central · Cited by 59
Veldhuis, J. D., Pincus, S. M., Garcia-Rudaz, M. C., Ropelato, M. G., Escobar, M. E., & Barontini, M. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.1.7125 · Cited by 54
Insulin-sensitising agents in polycystic-ovary syndrome
Sattar, N. A., Hopkinson, Z. E., & Greer, I. A. (1998) · The Lancet · doi:10.1016/s0140-6736(05)78345-8 · Cited by 50
Insulin resistance and thrombosis: a cardiologist’s view
Sobel, B. E. (1999) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)00357-4 · Cited by 50
Self-citationObstructive sleep apnea and metabolic dysfunction in polycystic ovary syndrome
Nitsche, K., & Ehrmann, D. A. (2010) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2010.08.001 · Cited by 55
Self-citationPeroxisome Proliferator‐Activated Receptors: New Players in the Field of Reproduction
Tóth, B., Hornung, D., Scholz, C., Djalali, S., Friese, K., & Jeschke, U. (2007) · American Journal of Reproductive Immunology · doi:10.1111/j.1600-0897.2007.00514.x · Cited by 53
PPAR‐γ signalling as a key mediator of human hair follicle physiology and pathology
Ramot, Y., Bertolini, M., Boboljova, M., Uchida, Y., & Paus, R. (2019) · Experimental Dermatology · doi:10.1111/exd.14062 · Cited by 49
Polycystic ovary syndrome: A review for dermatologists
Buzney, E. A., Sheu, J., Buzney, C. D., & Reynolds, R. V. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.05.009 · Cited by 56
Zhou, R., Bruns, C. M., Bird, I. M., Kemnitz, J. W., Goodfriend, T. L., Dumesic, D. A., & Abbott, D. H. (2007) · Reproductive Toxicology · doi:10.1016/j.reprotox.2006.12.009 · Cited by 51
Polycystic ovary syndrome—a systemic disorder?
Balen, A. H., & Rajkowha, M. (2003) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/s1521-6934(02)00119-0 · Cited by 57
Insulin resistance, insulin sensitization and inflammation in polycystic ovarian syndrome.
Dhindsa, G., Bhatia, R., Dhindsa, M., & Bhatia, V. (2004) · PubMed · Cited by 56
Genomic variants in polycystic ovary syndrome
Luque‐Ramírez, M., Millán, J. L. S., & Escobar-Morreale, H. F. (2005) · Clinica Chimica Acta · doi:10.1016/j.cca.2005.10.017 · Cited by 54
Branigan, E. F., & Estes, M. A. (2003) · American Journal of Obstetrics and Gynecology · doi:10.1067/mob.2003.459 · Cited by 52
Sobel, B. E. (1999) · Proceedings of the Association of American Physicians · doi:10.1046/j.1525-1381.1999.99231.x · Cited by 48
Self-citationMehta, R. V., Patel, K. S., Coffler, M. S., Dahan, M. H., Yoo, R. Y., Archer, J. S., Malcom, P. J., & Chang, R. J. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1040 · Cited by 47
Polycystic ovary syndrome: Current and future treatment paradigms
Legro, R. S. (1998) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(98)70240-6 · Cited by 58
Molecular Mysteries of Polycystic Ovary Syndrome
Strauss, J. F., & Dunaif, A. E. (1999) · Molecular Endocrinology · doi:10.1210/mend.13.6.0285 · Cited by 53
INSULIN-LOWERING THERAPEUTIC MODALITIES FOR POLYCYSTIC OVARY SYNDROME
Ehrmann, D. A. (1999) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(05)70078-5 · Cited by 48
Self-citationSiebert, T. I., Viola, M. I., Steyn, D. W., & Kruger, T. F. (2012) · Gynecologic and Obstetric Investigation · doi:10.1159/000335253 · Cited by 49
Turner, N. C., & Clapham, J. C. (1998) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-8845-5_2 · Cited by 63
Sills, E. S., Perloe, M., & Palermo, G. D. (2000) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/s0301-2115(99)00287-0 · Cited by 45
Troglitazone: A Possible Modulator of Ovarian Steroidogenesis
Mitwally, M. F., Witchel, S. F., & Casper, R. F. (2002) · Journal of the Society for Gynecologic Investigation · doi:10.1177/107155760200900308 · Cited by 44
Thiazolidinediones for Treatment of Polycystic Ovary Syndrome
Stout, D. L., & Fugate, S. E. (2005) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.25.2.244.56943 · Cited by 45
Androgens, cardiovascular risk factors and atherosclerosis
von Eckardstein, A. (1998) · Springer eBooks · doi:10.1007/978-3-642-72185-4_8 · Cited by 51
Nordt, T. K., Peter, K., Bode, C., & Sobel, B. E. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.4.6525 · Cited by 44
Self-citationGlintborg, D., Støving, R. K., Hagen, C., Hermann, A. P., Frystyk, J., Veldhuis, J. D., Flyvbjerg, A., & Andersen, M. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0615 · Cited by 43
Magzoub, R., Kheirelseid, E. A. H., Perks, C. M., & Lewis, S. J. (2022) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2022.01.025 · Cited by 49
Comparison of metformin versus rosiglitazone in patients with Acanthosis nigricans: a pilot study.
Bellot-Rojas, P., Posadas‐Sánchez, R., Caracas-Portilla, N., Zamora‐González, J., Cardoso-Saldaña, G. C., Cruz, F. J., & Posadas‐Romero, C. (2006) · PubMed · Cited by 42
Polycystic Ovary Syndrome and Hyperandrogenic States
Chang, R. J., & Dumesic, D. A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-47912-7.00021-4 · Cited by 49
Physiology and Pathology of the Female Reproductive Axis
Bulun, S. E. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0324-5.00017-1 · Cited by 48
Chao, T., Li, Y., Chen, J.-H., Wu, H., Shi, G.-Y., Liu, P., Tsai, W., & Guo, H. (2004) · Clinical Science · doi:10.1042/cs20040014 · Cited by 41
Pharmacologic Therapy of Polycystic Ovary Syndrome
Dronavalli, S., & Ehrmann, D. A. (2007) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0b013e31802f35a0 · Cited by 41
Self-citationSteroidogenic alterations and adrenal androgen excess in PCOS
Doi, S. A. R., Al-Zaid, M. M., Towers, P. A., Scott, C., & Al-Shoumer, K. A. S. (2006) · Steroids · doi:10.1016/j.steroids.2006.05.005 · Cited by 41
Ehrmann, D. A., Breda, E., Cavaghan, M. K., Bajramovic, S., Imperial, J., TOFFOLO, G. M., Cobelli, C., & Polonsky, K. S. (2002) · Diabetologia · doi:10.1007/s00125-002-0776-y · Cited by 45
Self-citationMinge, C. E., Ryan, N. K., der Hoek, K. H. V., Robker, R. L., & Norman, R. J. (2005) · Biology of Reproduction · doi:10.1095/biolreprod.105.043729 · Cited by 44
Menstrual Health and the Metabolic Syndrome in Adolescents
Tfayli, H. M., & Arslanian, S. A. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1429.024 · Cited by 45
Antoine, H. J., Pall, M., Trader, B. C., Chen, Y. I., Azziz, R., & Goodarzi, M. O. (2006) · Fertility and Sterility · doi:10.1016/j.fertnstert.2006.10.006 · Cited by 44
Polycystic ovary syndrome in adolescents: is there an epidemic?
Arslanian, S. A., & Witchel, S. F. (2002) · Current Opinion in Endocrinology & Diabetes · doi:10.1097/00060793-200202000-00006 · Cited by 45
Gottschling-Zeller, H., Röhrig, K., & Hauner, H. (2000) · Diabetologia · doi:10.1007/s001250050057 · Cited by 41
The New Antidiabetic Drug MCC-555 Acutely Sensitizes Insulin Signaling in Isolated Cardiomyocytes
Liu, L. S., Tanaka, H., Ishii, S., & Eckel, J. (1998) · Endocrinology · doi:10.1210/endo.139.11.6310 · Cited by 39
Current lead natural products for the chemotherapy of human immunodeficiency virus (HIV) infection
De Clercq, E. (2000) · Medicinal Research Reviews · doi:10.1002/1098-1128(200009)20:5<323::aid-med1>3.0.co;2-a · Cited by 355
TREATMENT FOR THE PROCOAGULANT STATE IN TYPE 2 DIABETES
Colwell, J. A. (2001) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(05)70225-5 · Cited by 39
Cardiovascular Risk Factors Associated with Insulin Resistance: Effects of Oral Antidiabetic Agents
Granberry, M. C., & Fonseca, V. A. (2005) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200505030-00006 · Cited by 38
Nonalcoholic fatty liver disease and obstructive sleep apnea in women with polycystic ovary syndrome
Doycheva, I., & Ehrmann, D. A. (2022) · Fertility and Sterility · doi:10.1016/j.fertnstert.2022.03.020 · Cited by 40
Self-citationAndrogen-induced epigenetic modulations in the ovary
Salinas, I., Sinha, N., & Sen, A. (2021) · Journal of Endocrinology · doi:10.1530/joe-20-0578 · Cited by 37
Second World Congress on the Insulin Resistance Syndrome
Bloomgarden, Z. T. (2005) · Diabetes Care · doi:10.2337/diacare.28.7.1821 · Cited by 36
INSULIN-LOWERING MEDICATIONS IN POLYCYSTIC OVARY SYNDROME
Taylor, A. E. (2000) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/s0889-8545(05)70157-1 · Cited by 40
Silva, R. D. C., Pardini, D., & Kater, C. E. (2006) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302006000200014 · Cited by 75
Carmassi, F., Morale, M., Ferrini, L., Dell’Omo, G., Ferdeghini, M., Pedrinelli, R., & Negri, F. D. (1999) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00240-5 · Cited by 36
Sharma, I., & Singh, D. (2012) · Reproduction · doi:10.1530/rep-12-0079 · Cited by 35
Stress in Women: Metabolic Syndrome and Polycystic Ovary Syndrome
Diamanti‐Kandarakis, E., & Economou, F. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1367.006 · Cited by 39
Unluhizarci, K., Keleştimur, F., Sahin, Y., & Bayram, F. (1999) · European Journal of Endocrinology · doi:10.1530/eje.0.1400056 · Cited by 36
Insulin and polycystic ovary syndrome: A new look at an old subject
Ciampelli, M., & Lanzone, A. (1998) · Gynecological Endocrinology · doi:10.3109/09513599809015601 · Cited by 42
The pathogenesis of polycystic ovary syndrome: Lessons from ovarian stimulation studies
Barnes, R. B. (1998) · Journal of Endocrinological Investigation · doi:10.1007/bf03350782 · Cited by 37
Use of Insulin-Sensitizing Agents in Patients With Polycystic Ovary Syndrome
Bloomgarden, Z. T., Futterweit, W., & Poretsky, L. (2001) · Endocrine Practice · doi:10.4158/ep.7.4.279 · Cited by 34
Ihara, H., Urano, T., Takada, A., & Loskutoff, D. J. (2001) · The FASEB Journal · doi:10.1096/fj.00-0570fje · Cited by 36
Clinical evidence that hyperinsulinaemia independent of gonadotropins stimulates ovarian growth
Musso, C., Shawker, T. H., Cochran, E. K., Javor, E. D., Young, J. R., & Görden, P. (2005) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2005.02302.x · Cited by 33
The Biological Variation of Insulin Resistance in Polycystic Ovarian Syndrome
Jayagopal, V., Kilpatrick, E. S., Holding, S., Jennings, P. E., & Atkin, S. L. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.4.8404 · Cited by 33
Insulin resistance and the polycystic ovary syndrome
Hao, G. (2005) · Journal of reproductive medicine · Cited by 33
Krentz, A. J. (2009) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.937 · Cited by 32
Zangeneh, F., Kudva, Y. C., & Basu, A. (2003) · Mayo Clinic Proceedings · doi:10.4065/78.4.471 · Cited by 47
The Fat Mouse: A Powerful Genetic Model to Study Hemostatic Gene Expression in Obesity/NIDDM
Loskutoff, D. J., Fujisawa, K., & Samad, F. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06322.x · Cited by 32
Clinical implications of the insulin resistance syndrome
Garvey, W. T., & Hermayer, K. L. (1998) · Clinical cornerstone · doi:10.1016/s1098-3597(98)90015-1 · Cited by 38
Risk of Cardiovascular Events in Mothers of Women with Polycystic Ovary Syndrome
Cheang, K. I., Nestler, J. E., & Futterweit, W. (2008) · Endocrine Practice · doi:10.4158/ep.14.9.1084 · Cited by 31
Garmes, H. M., Tambascia, M. A., & Zantut‐Wittmann, D. E. (2005) · Gynecological Endocrinology · doi:10.1080/09513590500430575 · Cited by 31
Ibáñez, L., Aulesa, C., Potau, N., Ong, K. K., Dunger, D. B., & de Zegher, F. (2002) · Pediatric Research · doi:10.1203/00006450-200202000-00019 · Cited by 36
Gonadotropins at menopause: the influence of obesity, insulin resistance, and estrogens
Malacara, J. M., Fajardo, M. E., & Nava, L. E. (2001) · Steroids · doi:10.1016/s0039-128x(00)00223-3 · Cited by 30
Saturated fatty acid exposure induces androgen overproduction in bovine adrenal cells
Bellanger, S., Battista, M., Fink, G. D., & Baillargeon, J. (2012) · Steroids · doi:10.1016/j.steroids.2011.12.017 · Cited by 34
Effects of the Thiazolidinediones on Cardiovascular Risk Factors
Gilling, L., Suwattee, P., Desouza, C. V., Asnani, S., & Fonseca, V. A. (2002) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200202030-00002 · Cited by 29
Rautio, K., Tapanainen, J. S., Ruokonen, A., & Morin-Papunen, L. C. (2006) · Fertility and Sterility · doi:10.1016/j.fertnstert.2006.05.061 · Cited by 30
The long term health consequences of polycystic ovary syndrome
Kelly, C. J. G., Connell, J., Cameron, I. T., Gould, G. W., & Lyall, H. (2000) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.2000.tb11644.x · Cited by 34
Metformin and intervention in polycystic ovary syndrome
Norman, R. J., Kidson, W., Cuneo, R. C., Zacharin, M., & Endocrine Society of Australia, T. A. D. S. A. T. A. P. E. G. (2001) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2001.tb143439.x · Cited by 29
The polycystic ovary syndrome: the first 150 years of study
Adashi, E. Y., Cibula, D., Peterson, M., & Azziz, R. (2022) · F&S Reports · doi:10.1016/j.xfre.2022.12.002 · Cited by 38
Valsamakis, G., Lois, K., Kumar, S., & Mastorakos, G. P. (2013) · HORMONES · doi:10.1007/bf03401302 · Cited by 30
Diabetes treatments have differential effects on nontraditional cardiovascular risk factors
Fonseca, V. A., Theuma, P., Mudaliar, S. R., Leissinger, C., Clejan, S., & Henry, R. R. (2005) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2005.05.009 · Cited by 30
Polycystic Ovary Syndrome—Increased or Preserved Ovarian Sensitivity to Insulin?
Poretsky, L. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0317 · Cited by 27
Weiss, J. M., Polack, S., Diedrich, K., & Ortmann, O. (2003) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-003-0506-9 · Cited by 27
Ovarian steroids modulate neuroendocrine dysfunction in polycystic ovary syndrome
Doi, S. A. R., Al-Zaid, M., Towers, P. A., Scott, C. J., & Al-Shoumer, K. A. S. (2005) · Journal of Endocrinological Investigation · doi:10.1007/bf03345319 · Cited by 26
Aso, Y., Yamamoto, R., Suetsugu, M., Matsumoto, S., Wakabayashi, S., Matsutomo, R., Takebayashi, K., & Inukai, T. (2007) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02204.x · Cited by 26
Current Views on the Mechanism of Action of Thiazolidinedione Insulin Sensitizers
Goldstein, B. J. (1999) · Diabetes Technology & Therapeutics · doi:10.1089/152091599317189 · Cited by 26
Neuroendocrine Dysfunction in PCOS: A Critique of Recent Reviews
Doi, S. A. R. (2008) · Clinical Medicine & Research · doi:10.3121/cmr.2008.796 · Cited by 30
Glitazones and the management of insulin resistance: what they do and how might they be used
EINHORN, D. F., Aroda, V. R., & Henry, R. R. (2004) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2004.04.003 · Cited by 27
Polycystic Ovary Syndrome and Chronic Inflammation: Pharmacotherapeutic Implications
Sirmans, S. M., Weidman-Evans, E., Everton, V., & Thompson, D. (2012) · Annals of Pharmacotherapy · doi:10.1345/aph.1q514 · Cited by 25
Inositolphosphoglycans (IPGs) as Mediators of Insulin's Steroidogenic Actions
Nestler, J. E. (1998) · Journal of Basic and Clinical Physiology and Pharmacology · doi:10.1515/jbcpp.1998.9.2-4.197 · Cited by 29
Insulin resistance in polycystic ovary syndrome: treating a phenotype without a genotype
Legro, R. S. (1998) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(98)00176-2 · Cited by 27
The Polycystic Ovary Syndrome: Current Concepts On Pathogenesis And Clinical Care
Azziz, R. (2007) · Springer eBooks · doi:10.1007/978-0-387-69248-7 · Cited by 29
McCartney, C. R., Bellows, A. B., Gingrich, M. B., Hu, Y. F., Evans, W. S., Marshall, J. C., & Veldhuis, J. D. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00415.2003 · Cited by 30
Peroxisome proliferator-activated receptor γ: Its role in metabolic syndrome
Pakala, R., Kuchulakanti, P. K., Rha, S., Cheneau, E. F., Baffour, R., & Waksman, R. (2004) · Cardiovascular Radiation Medicine · doi:10.1016/j.carrad.2004.03.006 · Cited by 27
Wagenaar, L. J., Kuck, E. M., & Hoekstra, J. B. (1999) · The Netherlands Journal of Medicine · doi:10.1016/s0300-2977(99)00021-2 · Cited by 25
Ciotta, L., Leo, V. D., Galvani, F., Marca, A. L., & Cianci, A. (1999) · Human Reproduction · doi:10.1093/humrep/14.12.2951 · Cited by 29
Insulin resistance and the polycystic ovary syndrome: recent advances
Nestler, J. E. (2000) · Current Opinion in Endocrinology & Diabetes · doi:10.1097/00060793-200012000-00009 · Cited by 25
Wang, H., & Wang, T. (2003) · PubMed · Cited by 27
Kumarendran, B., O’Reilly, M., Subramanian, A., Šumilo, D., Toulis, K. A., Gokhale, K. M., Wijeratne, C. N., Coomarasamy, A., Tahrani, A. A., Azoulay, L., et al. (2021) · Diabetes Care · doi:10.2337/dc21-0437 · Cited by 26
CHRISTOPOULOS, P. F., Mastorakos, G. P., Gazouli, M., Deligeoroglou, E., Katsikis, I., Diamanti‐Kandarakis, E., Panidis, D., & Creatsas, G. C. (2010) · Gynecological Endocrinology · doi:10.3109/09513591003649823 · Cited by 23
Rasouli, N., Kern, P. A., Reece, E. A., & Elbein, S. C. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00221.2006 · Cited by 23
Metadata
- Authors
- Ehrmann, D. A., Schneider, D. J., Sobel, B. E., Cavaghan, M. K., Imperial, J., Rosenfield, R. L., & Polonsky, K. S.
- Affiliations
- University of Chicago (US)
- University of Vermont (US)
- Corresponding author
- Ehrmann, David A.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 1997-07
- Volume
- 82
- Issue
- 7
- Pages
- 2108-2116
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2073637312
- Cited by
- 461
- References
- 67
- Citations by year
- 2025: 2 · 2024: 3 · 2022: 6 · 2021: 2 · 2019: 3 · 2018: 2 · 2017: 2 · 2016: 7 · 2015: 2 · 2014: 5 · 2013: 10 · 2012: 11
- FWCI
- 36.83
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5k08dk002315-02)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK-31842, DK 20595, DK-02315)
- NIH Clinical Center
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic and Kidney Cyst Diseases
- Keywords
- troglitazone, polycystic ovary syndrome, insulin resistance, insulin secretion, beta-cell function, ovarian steroidogenesis, fibrinolysis, plasminogen activator inhibitor-1, tissue plasminogen activator, hyperinsulinemia, impaired glucose tolerance, insulin sensitizers, hyperandrogenemia, obese women, leuprolide
- MeSH terms
- Troglitazone, Adult, Androgens, Chromans, Female, Fibrinolysis, Glucose, Glucose Tolerance Test, Gonadotropins, Humans, Insulin, Insulin Resistance, Polycystic Ovary Syndrome, Thiazoles, Leuprolide, Plasminogen Activator Inhibitor 1, Thiazolidinediones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.